SGLT2 inhibitors after transcatheter aortic valve implantation. A systematic review and exploratory meta-analysis

.1. Background Transcatheter aortic valve implantation (TAVI) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) represent two major advances in contemporary cardiovascular care [1], [2], [3], [4]. Despite procedural success, patients undergoing TAVI remain at substantial residual risk of mortality and heart failure (HF) events, providing a rationale for adjunctive pharmacological strategies in this setting [1], [2], [5]. The DapaTAVI trial recently provided the first randomized evidence suggesting that dapagliflozin initiated after TAVI may reduce the risk of death or worsening HF [2], [3]. In parallel, several observational studies have explored the real-world impact of SGLT2i therapy following TAVI, reporting heterogeneous associations with clinical outcomes [6], [7], [8], [9]. 2. Aims The primary aim of this study was to provide a structured systematic review of the available evidence on SGLT2i use in patients undergoing TAVI, with a secondary, exploratory quantitative synthesis of outcomes.